These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 9664992

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.
    Liver Transpl; 2005 Jan; 11(1):61-7. PubMed ID: 15690537
    [Abstract] [Full Text] [Related]

  • 3. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
    Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, Bain V, Ghent C, Marotta P, Grant D, Wall W, Tchervenkov J, Barkun J, Roy A, Marleau D, McAlister V, Peltekian K.
    Liver Transpl; 2003 Jun; 9(6):587-95. PubMed ID: 12783400
    [Abstract] [Full Text] [Related]

  • 4. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G, Glyda M, Albano L, Viklický O, Merville P, Tydén G, Mourad M, Lõhmus A, Witzke O, Christiaans MHL, Brown MW, Undre N, Kazeem G, Kuypers DRJ, Advagraf-based immunosuppression regimen examining new onset diabetes mellitus in kidney transplant recipients (ADVANCE) study investigators.
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study.
    Podesser BK, Rinaldi M, Yona NA, Pulpón LA, Villemot JP, Haverich A, Duveau D, Brandrup-Wognsen G, Gronda E, Costard-Jäckle A, Crespo-Leiro MG, Khazen CS, Viganó M, Segovia J, Mattei MF, Harringer W, Treilhaud M, Karason K, Mangiavacchi M, Laufer G.
    Transplantation; 2005 Jan 15; 79(1):65-71. PubMed ID: 15714171
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J.
    Liver Transpl; 2004 Jun 15; 10(6):728-33. PubMed ID: 15162466
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study.
    Lladó L, González-Castillo A, Fabregat J, Baliellas C, Ramos E, González-Vilatarsana E, Busquets J, Xiol X.
    Ann Transplant; 2019 Jan 18; 24():36-44. PubMed ID: 30655498
    [Abstract] [Full Text] [Related]

  • 17. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients.
    Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, Scheller D, Ersfeld D, Frick M, Fitzsimmons WE, Virji M, Jain A, Brayman KL, Shaked A.
    J Clin Pharmacol; 2001 May 18; 41(5):542-51. PubMed ID: 11361051
    [Abstract] [Full Text] [Related]

  • 18. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
    Wagner K, Webber SA, Kurland G, Boyle GJ, Miller SA, Cipriani L, Griffith BP, Fricker FJ.
    J Heart Lung Transplant; 1997 Mar 18; 16(3):275-82. PubMed ID: 9087870
    [Abstract] [Full Text] [Related]

  • 19. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation.
    Castedal M, Skoglund C, Axelson C, Bennet W.
    Scand J Gastroenterol; 2018 Jun 18; 53(6):741-747. PubMed ID: 29688072
    [Abstract] [Full Text] [Related]

  • 20. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation.
    Cacciarelli TV, Esquivel CO, Cox KL, Hayashi M, Berquist WE, Concepcion W, So SK.
    Transplantation; 1996 Apr 27; 61(8):1188-92. PubMed ID: 8610416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.